Książki na temat „POTENTIAL INHIBITORS”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: POTENTIAL INHIBITORS.

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych książek naukowych na temat „POTENTIAL INHIBITORS”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj książki z różnych dziedzin i twórz odpowiednie bibliografie.

1

Casey, Lorraine A. The synthesis of potential enzyme inhibitors. Huddersfield: The Polytechnic, 1991.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Johnson, N. B. Modified peptides as potential enzyme inhibitors. Manchester: UMIST, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Noort, Daniël. Design, synthesis, and evaluation of potential inhibitors of UDP-glucuronosyltransferase. [The Netherlands: s.n.], 1992.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

International Symposium on Proteases: Potential Role in Health and Disease (2nd 1987 Rothenburg ob der Tauber, Germany). Proteases II: Potential role in health and disease. New York: Plenum Press, 1988.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

1930-, Smith H. J., i Simons Claire, red. Proteinase and peptidase inhibition: Recent potential targets for drug development. London: Taylor & Francis, 2002.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Wiggins, Karen. Synthesis of potential phospholipase A2 inhibitors based on manoalide. Norwich: University of East Anglia, 1989.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Yap, Chee Hoong. Potential inhibitors of dihydrofolate reductase: Synthesis and NMR spectroscopy. Birmingham: University of Aston. Department of Molecular Sciences (Chemistry), 1985.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

1943-, Greenwald Robert A., Golub Lorne M i New York Academy of Sciences., red. Inhibition of matrix metalloproteinases: Therapeutic potential. New York, N.Y: New York Academy of Sciences, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Quibell, Martin. The synthesis of azaglutamine containing peptides as potential inhibitors of the picornavirus 3C proteinase. Birmingham: University of Birmingham, 1991.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Surfraz, Mohammad Bashir-Uddin. Design and synthesis of novel inhibitors of Inositol Monophosphatase: Potential drug candidates in the treatment of Bipolar Disorder. Birmingham: University of Birmingham, 2003.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
11

Isaacs, Stuart Neal. Premeditated enzyme inactivation: The development of mechanism-based irreversible inhibitors of glyoxalase I as potential anti-cancer agents. [New Haven: s.n.], 1985.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
12

Morlin, A. J. G. The preparation of some chiral 2-hydroxycarboxylic acids and their use in the synthesisof potential angiotensin converting enzyme inhibitors. Norwich: University of East Anglia, 1993.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
13

Wong, Philip. The potential of two new inhibitors of mechanisms that regulate intracellular pH, cariporide and S3705, to inhibit tumour cell proliferation. Ottawa: National Library of Canada, 2001.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
14

Athanasius, Anagostou, Dainiak Nicholas, Najman Albert i International Conference on Negative Regulators of Hematopoiesis, (2nd : 1990 : Providence, R.I.), red. Negative regulators of hematopoiesis: Studies of their nature, action, and potential role in cancer therapy. New York, N.Y: New York Academy of Sciences, 1991.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
15

R, Vane John, Botting Regina M, William Harvey Research Conference (1997 : Phuket, Thailand) i William Harvey Research Conference (1998 : Boston, Mass.), red. Clinical significance and potential of selective COX-2 inhibitors: The combined proceedings of the William Harvey Conferences held in Phuket, Thailand, on 18-19 September, 1997 and in Boston, USA, on 23-24 April, 1998, supported by an educational grant from Boehringer Ingelheim. London: William Harvey Press, 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
16

Souris, John. Synthesis of a potential bi-product analogue inhibitor for human plasma carboxypeptidase N. Sudbury, Ont: Laurentian University, 1985.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
17

Shuffrey, Lauren Christine. Electrophysiological Marker of a Potential Excitatory/Inhibitory Imbalance in Children with Autism Spectrum Disorder. [New York, N.Y.?]: [publisher not identified], 2017.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
18

Bates, Stephen Robert Edward. Potential inhibitors of zinc proteinases. 1985.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
19

Design of Caspase Inhibitors as Potential Clinical Agents (Enzyme Inhibitors). CRC, 2008.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
20

Allen, Andrew David. The atomistic simulation of potential angiogenic inhibitors. 1996.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
21

Mousa, Shaker A. Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications. Taylor & Francis Group, 2000.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
22

Linton, Steven D., i Tom O'Brien. Design of Caspase Inhibitors As Potential Clinical Agents. Taylor & Francis Group, 2008.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
23

Linton, Steven D., i Tom O'Brien. Design of Caspase Inhibitors As Potential Clinical Agents. Taylor & Francis Group, 2008.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
24

Linton, Steven D., i Tom O'Brien. Design of Caspase Inhibitors As Potential Clinical Agents. Taylor & Francis Group, 2019.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
25

Design of caspase inhibitors as potential clinical agents. Boca Raton: Taylor & Francis, 2009.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
26

Simons, Claire, H. John Smith i Steven D. Linton. Design of Caspase Inhibitors As Potential Clinical Agents. Taylor & Francis Group, 2008.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
27

(Editor), H. John Smith, i Claire Simons (Editor), red. Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development. CRC, 2002.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
28

Simons, Claire, i H. John Smith. Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development. Taylor & Francis Group, 2002.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
29

Simons, Claire, i H. John Smith. Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development. Taylor & Francis Group, 2002.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
30

Simons, Claire, i H. John Smith. Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development. Taylor & Francis Group, 2002.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
31

Simons, Claire, i H. John Smith. Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development. Taylor & Francis Group, 2002.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
32

Simons, Claire, i H. John Smith. Proteinase and Peptidase Inhibition: Recent Potential Targets for Drug Development. Taylor & Francis Group, 2002.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
33

Vane, Sir John, red. Clinical Significance And Potential Of Selective Cox-2 Inhibitors. WILLIAM HARVEY PRESS, 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
34

Sharma, Sushil K. Monoamine Oxidase Inhibitors: Clinical Pharmacology, Benefits, and Potential Health Risks. Nova Science Publishers, Incorporated, 2016.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
35

Mousa, Shaker A. Angiogenesis Inhibitors and Stimulators: Potential Therapeutic Implications (Medical Intelligence Unit). Landes Bioscience, 2000.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
36

Sir John R. Vane (Editor) i Jack H. Botting (Editor), red. Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. Springer, 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
37

Botting, Jack H., i Sir John R. Vane. Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential. Springer, 2012.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
38

(Editor), Walter H. Hörl, i August Heidland (Editor), red. Proteases II: Potential Role in Health and Disease (Advances in Experimental Medicine and Biology). Springer, 1989.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
39

Fleischmann, Roy. Signalling pathway inhibitors. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0081.

Pełny tekst źródła
Streszczenie:
Oral, small-molecule signalling pathway inhibitors, including ones that inhibit the JAK and SyK pathways, are currently in development for the treatment of rheumatoid arthritis (RA). Tofacitinib is an orally administered small-molecule inhibitor that targets the intracellular Janus kinase 3 and 1 (JAK1/3) molecules to a greater extent than JAK2 while baricitinib (formerly INCB028050) predominantly inhibits JAK1/2. Many of the proinflammatory cytokines implicated in the pathogenesis of RA utilize cell signalling that involves the JAK-STAT pathways and therefore inhibition of JAK-STAT signalling, by targeting multiple RA-associated cytokine pathways, has the potential to simultaneously reduce inflammation, cellular activation, and proliferation of key immune cells. Fostamatinib disodium is an orally available inhibitor of spleen tyrosine kinase (SyK), which is a cytoplasmic tyrosine kinase that is an important mediator of immunoreceptor signalling in mast cells, macrophages, neutrophils, and B cells. Interruption of SyK signalling may interrupt production of tumour necrosis factor (TNF) and metalloproteinase and therefore affect RA disease activity. Tofacitinib has been investigated in multiple phase 2 and phase 3 trials which have investigated its efficacy (clinical, functional, and radiographic) and safety in patients who have failed disease-modifying anti-inflammatory drugs (DMARDs) as monotherapy or in combination with DMARDs, compared to an inhibitor of tumour necrosis factor alpha (TNFα‎) and in patients who have failed TNFα‎ inhibitors. The efficacy of fostamatinib and baricitinib has been investigated in phase 2 trials; both are in large phase 3 clinical programmes. Each of these medications has demonstrated efficacy; their safety profile has been shown to be different from each other and from currently approved biological agents. This chapter discusses what is currently known and understood about their efficacy and safety.
Style APA, Harvard, Vancouver, ISO itp.
40

Biotransformation Potential and Uncoupling Behavior of Common Benzotriazole-Based Corrosion Inhibitors. Storming Media, 2002.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
41

Onuigbo, Macaulay Amechi. ACE Inhibitors: Medical Uses, Mechanisms of Action, Potential Adverse Effects and Related Topics. Volume 1. Nova Science Publishers, Incorporated, 2015.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
42

(Editor), Robert A. Greenwald, New York Academy of Sciences (Corporate Author) i Lorne M. Golub (Editor), red. Inhibition of Matrix Metalloproteinases: Therapeutic Potential (Annals of the New York Academy of Sciences). New York Academy of Sciences, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
43

1st, Naga Raju Chinthakunta, Suresh Kumar Chitta 2nd, Anuradha C. M. 3rd i Rajani Vallepu IV. In Silico Screening of Natural Compounds As Potential Inhibitors of GPR120 to Prevent Cancer. INSC International Publisher (IIP), 2021.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
44

(Editor), Robert A. Greenwald, New York Academy of Sciences (Corporate Author) i Lorne M. Golub (Editor), red. Inhibition of Matrix Metalloproteinases: Therapeutic Potential (Annals of the New York Academy of Sciences, Vol 732). New York Academy of Sciences, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
45

Selective COX-2 inhibitors: Pharmacology, clinical effects, and therapeutic potential : proceedings of a conference held on March 20-21, 1997, in Cannes, France. Dordrecht: Kluwer Academic, 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
46

R, Vane John, Botting Jack H i William Harvey Research Conference (1997 : Cannes, France), red. Selective COX-2 inhibitors: Pharmacology, clinical effects and therapeutic potential : proceedings of a conference held on March 20-21, 1997, in Cannes, France. Dordrecht: Kluwer Academic, 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
47

Onuigbo, Macaulay Amechi. ACE Inhibitors: Medical Uses, Mechanisms of Action, Potential Adverse Effects and Related Topics -- Volume 1. Nova Science Publishers, Incorporated, 2013.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
48

Onuigbo, Macaulay Amechi. ACE Inhibitors: Medical Uses, Mechanisms of Action, Potential Adverse Effects and Related Topics -- Volume 2. Nova Science Publishers, Incorporated, 2013.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
49

Onuigbo, Macaulay Amechi, i Macaulay Amechi Chuka Onuigbo. ACE Inhibitors: Medical Uses, Mechanisms of Action, Potential Adverse Effects and Related Topics. Volume 2. Nova Science Publishers, Incorporated, 2015.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
50

Regulation of Carcinogenesis, Angiogenesis and Metastasis by the Proprotein Convertases (PC's): A New Potential Strategy in Cancer Therapy. Springer, 2006.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii